证券代码：688266 证券简称：泽璟制药 公告编号：2024-046 苏州泽璟生物制药股份有限公司 关于召开 2024 年度第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 投资者可于 2024 年 11 月 25 日（星期一）至 12 月 2 日（星期一）16:00 前登录上证路演中心网站首页点击 "提问预征集"栏目或通过公司邮箱 zelgen01@zelgen.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 苏州泽璟生物制药股份有限公司（以下简称"公司"）已于 2024 年 10 月 26 日发布公司《2024 年第三季度报告》，为便于广大投资者更全面深入地了解公司 2024 年第三季度经营成果、财务状况，公司计划于 2024 年 12 月 3 日下午 15:00-16:00 举行 2024 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2024 年第三季度经营 成果及财务指标的具体 ...

Investment Rating - The investment rating for the company is "Accumulate" [2][4]. Core Views - The company is experiencing accelerated product volume and significantly reduced losses, with core pipelines entering a harvest phase [3][4]. - The early pipeline is steadily advancing, expected to catalyze a new growth cycle [3][4]. Financial Summary - The company achieved revenue of 384 million yuan in Q1-Q3 2024, representing a year-on-year increase of 36.16%. Q3 revenue reached 143 million yuan, up 130.67% year-on-year and 8.28% quarter-on-quarter, driven by the product Donafenib [4]. - The net loss for Q1-Q3 2024 was 98 million yuan, a reduction of 104 million yuan year-on-year, indicating a trend towards reduced losses [4]. - The EPS forecasts for 2024-2026 are -0.63, 0.30, and 1.49 yuan, respectively, with a target price maintained at 75.02 yuan, corresponding to a 29X PS for 2024 [4]. Product Pipeline - The company's core product, recombinant human thrombin, was approved for market launch in January 2024, characterized by high purity and hemostatic activity [4]. - The JAK inhibitor, Jikaxitinib, is currently under review for market approval, with multiple indications for autoimmune diseases progressing [4]. - The early pipeline includes ZG006, a trispecific antibody targeting DLL3, showing promising efficacy in early clinical trials [4]. Market Data - The current stock price is 62.94 yuan, with a target price of 75.02 yuan [2]. - The market capitalization is 16.661 billion yuan, with a total share capital of 265 million shares [5]. Financial Projections - Revenue projections for 2024, 2025, and 2026 are 699 million, 1.313 billion, and 2.257 billion yuan, respectively, with significant growth rates anticipated [9]. - The net profit (attributable to the parent company) is projected to improve from a loss of 168 million yuan in 2024 to a profit of 395 million yuan in 2026 [9]. Operational Efficiency - The company has improved operational efficiency, with a notable decrease in sales expense ratio and a decrease in R&D expense ratio due to the completion of several clinical registrations [4].

证券代码：688266 证券简称：泽璟制药 苏州泽璟生物制药股份有限公司 投资者关系活动记录表 编号：2024-009 | --- | --- | --- | |------------|------------------------|----------------------------------------------------------------------| | | | | | 投资者关系 | □ | 特定对象调研 √分析师会议 | | 活动类别 | □ 媒体采访 √业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □ 现场参观 □一对一沟通 | | | | □其他 | | | 参与单位 | | 广发证券、浙商证券、信达证券、华安证券、华西证券、开源证券、东吴证 | | 及人员 | | 券、华源证券、天风证券、国盛证券、海通证券、中信证券、中信建投、兴业 | | | | 证券、财通证券、上海盘京投资、新华基金、中信保诚基金、砥俊资产、德邦 | | | | 基金、中航基金、深圳市恒盈富达资产、西藏源乘投资、浙江银万斯特投 | | | | 资、上海银倍投资、摩根基金、杭州优 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company has shown steady revenue growth and is actively advancing innovative products [2] - Significant improvements in efficiency and quality have been achieved, with a focus on core pipeline development [2] - The company is expected to enter a new growth phase with upcoming innovative products [3] Financial Performance Summary - For the first three quarters of 2024, the company achieved revenue of 384 million yuan, a year-on-year increase of 36.16%, with a net profit attributable to shareholders of -98 million yuan, indicating a narrowing loss [1] - In the third quarter of 2024 alone, revenue reached 143 million yuan, a year-on-year increase of 130.67%, with a net profit attributable to shareholders of -31 million yuan, also showing a narrowing loss [1] - Research and development expenses for the first three quarters of 2024 were 273 million yuan, down 18.62% year-on-year, while sales expenses increased by 10.15% to 190 million yuan [2] Future Growth Potential - The company has several innovative products in the pipeline, including Donafenib, which has entered 1,081 hospitals and is gradually expanding its market share [3] - Other products such as recombinant human thrombin and JAK inhibitors are in various stages of clinical trials and regulatory approval, indicating a robust pipeline [3][4] - Early data from innovative pipelines show promising results, providing a competitive advantage globally [4] Earnings Forecast - The company is projected to achieve total revenues of 548 million yuan, 1.15 billion yuan, and 1.96 billion yuan for 2024, 2025, and 2026, respectively, with year-on-year growth rates of 41.79%, 109.33%, and 70.60% [5] - The net profit attributable to shareholders is expected to be -121 million yuan in 2024, turning positive in 2025 with a profit of 76 million yuan, and reaching 368 million yuan in 2026 [5] - The current stock price corresponds to a price-to-earnings ratio (P/E) of 219.39 for 2025 and 44.98 for 2026, reflecting the anticipated growth [5]

好的 谢谢会议助理尊敬的投资者 大家上午好欢迎参加由广化政权组织的2024年紫禁之要的三级报的一级交流会我是分享交流的组织之一李安飞然后跟我一起在线的还有我们首席联合老师以及我们研究员袁权 本场交流呢我们非常荣幸的邀请到了公司的董事长董经理盛博副总经理化学执行副总裁吕博副总经理董事会秘书高总副总经理财务负责人黄总营销副总营销副总裁冰总欢迎几位领导那跟我 跟我一起主持的还有几位友商的老师我就不一一的介绍了接下来我们把时间交给吕博吕博有请好的谢谢尊敬的各位投资人我是浙江资料局编号下面我向大家报告一下公司近三季度的一些业绩及管线的进展以及业绩的相关的情况 我的汇报大概分四个部分,公司概创、核心产品研发策略跟商业策略。公司的基本情况可能大家都比较清楚,折卷资料是成立于2009年3月的一家创新资料公司,主要专注于肿瘤、出血及粘血疾病与炎症性疾病等等多个资料领域、多个创新产品的研发的一个信仰开发公司。 我们致力于研发和生产具有全民自主自治产权安全有效患者可负担的创新药物那到目前为止我们已经有14个主要的在营药品已经有4个药品包括多拉菲尼虫族人凝血酶已经上市两个药品杰卡西帕尼和虫族人畜甲状腺素等多项实验证处于上市申请阶段 ...

Investment Rating - Maintains a "Buy" rating for the company [1][2] Core Views - Q3 revenue showed steady sequential growth, with a year-on-year increase of 130.67% [1] - The company's revenue for Q1-3 2024 reached 3.84 billion yuan, a year-on-year increase of 36.16% [2] - Net profit attributable to the parent company in Q3 was -0.31 billion yuan, with a sequential growth of 8.28% [2] - The company is expected to achieve revenues of 6.06/11.00/18.95 billion yuan in 2024-2026, with year-on-year growth rates of 56.9%/81.4%/72.4% [2] - The current stock price corresponds to a PS ratio of 29.0/16.0/9.3 times for 2024-2026 [1] Product and Market Expansion - The company has actively promoted the entry of its product, Donafenib, into hospitals and pharmacies, covering 1,081 hospitals and 934 pharmacies by the end of June 2024 [3] - The recombinant human thrombin product has been authorized to Yuanda Life Sciences, with the company receiving an exclusive market promotion fee of 340 million yuan in H1 2024 [3] Pipeline Progress - The late-stage pipeline is progressing steadily, with the flagship product, Gicartinib, having submitted an NDA for myelofibrosis [4] - The Phase III clinical trial for severe alopecia areata has reached the 24-week primary efficacy endpoint, with NDA submission expected after 52-week data readout [4] - The Phase II clinical study for idiopathic pulmonary fibrosis has achieved positive results [4] - The early-stage pipeline, ZG006 (CD3×DLL3×DLL3 trispecific antibody), showed an ORR of 66.7% and a DCR of 88.9% in I/II phase clinical studies for advanced small cell lung cancer or neuroendocrine carcinoma [4] Financial Projections - Revenue for 2024-2026 is projected to be 606/1,100/1,895 million yuan, with year-on-year growth rates of 56.9%/81.4%/72.4% [5] - Net profit attributable to the parent company is expected to be -457/-279/-152 million yuan in 2024-2026, with a significant turnaround to 175 million yuan in 2026 [5] - Gross margin is expected to remain stable at 93.0% from 2024 to 2026 [5] - EPS is projected to be -0.57/0.01/0.66 yuan for 2024-2026 [5] Valuation Metrics - The current stock price corresponds to a PS ratio of 29.0/16.0/9.3 times for 2024-2026 [1] - The PB ratio is expected to be 11.9/11.8/10.6 times for 2024-2026 [5]

证券代码：688266 证券简称：泽璟制药 公告编号：2024-045 苏州泽璟生物制药股份有限公司 关于注销部分募集资金专项账户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 苏州泽璟生物制药股份有限公司（以下简称"公司"）首次公开发行股票募集 资金按照相关法律、法规和规范性文件的规定在银行开立了募集资金专项账户。 近日，公司完成了部分首次公开发行股票募集资金专项账户的注销手续，具体情 况如下： 一、募集资金基本情况 根据中国证券监督管理委员会 2019 年 12 月 31 日作出的《关于同意苏州泽 璟生物制药股份有限公司首次公开发行股票注册的批复》（证监许可[2019]2998 号），公司向社会公开发行人民币普通股 60,000,000 股，每股发行价格为 33.76 元（人民币，下同），募集资金总额为 202,560.00 万元，扣除承销及保荐费用、 发行登记费以及累计发生的其他相关发行费用（共计 11,737.92 万元，不含税） 后，募集资金净额为 190,822.08 万元，上述资金已全部到位。信永中和 ...

Investment Rating - Investment Rating: Buy (Maintained) [1] Core Views - The company reported a revenue of 384 million yuan for Q3 2024, representing a year-on-year increase of 36.16% [1] - The net profit attributable to shareholders was -98 million yuan, showing a reduction in losses by 51.55% [1] - The company has achieved continuous quarter-on-quarter revenue growth over the past four quarters [1] - The gross margin for the first three quarters of 2024 was 92.96%, an increase of 0.57 percentage points year-on-year [1] - The company’s innovative drug ZG006 has shown promising clinical trial results, positioning it as a leading product in the TCE antibody sector [1] Financial Performance - Revenue projections for 2024-2026 are 588 million, 1.286 billion, and 2.059 billion yuan, with year-on-year growth rates of 52.3%, 118.5%, and 60.2% respectively [2] - The net profit attributable to shareholders is projected to be -127 million, 104 million, and 245 million yuan for the same period, with year-on-year growth rates of 54.6%, 182.0%, and 136.0% respectively [2] - The overall gross margin is expected to remain high, with estimates of 92.6% in 2024 and 91.2% in 2026 [3][4] Clinical Development - ZG006 has completed the dose escalation phase of its clinical trial for SCLC and neuroendocrine cancers, with 24 evaluable samples and a promising overall response rate (ORR) of 66.7% [1] - The drug has received orphan drug designation from the FDA, highlighting its global competitiveness [1] - The combination of ZG006 with frontline therapies is anticipated to enhance patient outcomes, supported by data from other CD3/DLL3 targeted therapies [1]

单位：人民币万元 | | | 证券代码：688266 证券简称：泽璟制药 公告编号：2024-044 苏州泽璟生物制药股份有限公司 关于部分募投项目延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 苏州泽璟生物制药股份有限公司（以下简称"泽璟制药"或"公司"）于 2024 年 10 月 25 日召开第二届董事会第十七次会议、第二届监事会第十六次会议，审 议通过了《关于部分募投项目延期的议案》，同意公司对"新药研发生产中心二 期工程建设项目"达到预定可使用状态的时间进行延期。保荐机构中国国际金融 股份有限公司出具了无异议的核查意见。该事项无需提交股东大会审议。 一、募集资金基本情况 根据中国证券监督管理委员会 2019 年 12 月 31 日作出的《关于同意苏州泽 璟生物制药股份有限公司首次公开发行股票注册的批复》（证监许可[2019]2998 号），公司向社会公开发行人民币普通股 60,000,000 股，每股发行价格为 33.76 元（人民币，下同），募集资金总额为 202,560.00 万元，扣除承销及保荐费 ...

中国国际金融股份有限公司 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为苏州泽 璟生物制药股份有限公司（以下简称"泽璟制药"或"公司"）的保荐机构，根据《证 券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市规则》以及《上海证 券交易所科创板上市公司自律监管指引第 1 号——规范运作》等法律法规，对泽璟制药 部分募投项目延期的事项进行了认真、审慎核查，具体情况如下： 关于苏州泽璟生物制药股份有限公司 部分募投项目延期的核查意见 一、募集资金基本情况 （一）募集资金基本情况 根据中国证券监督管理委员会 2019 年 12 月 31 日作出的《关于同意苏州泽璟生物 制药股份有限公司首次公开发行股票注册的批复》（证监许可[2019]2998 号），公司向社 会公开发行人民币普通股 60,000,000 股，每股发行价格为 33.76 元（人民币，下同）， 募集资金总额为 202,560.00 万元，扣除承销及保荐费用、发行登记费以及累计发生的其 他相关发行费用（共计 11,737.92 万元，不含税）后，募集资金净额为 190,822.08 万元， 上述资金已全部到位。信永中和会计师事务 ...